Literature DB >> 35767653

Delivery of therapeutic carbon monoxide by gas-entrapping materials.

James D Byrne1,2,3,4,5,6,7, David Gallo8, Hannah Boyce1, Sarah L Becker1, Kristi M Kezar9, Alicia T Cotoia9, Vivian R Feig1, Aaron Lopes1,2,3, Eva Csizmadia8, Maria Serena Longhi10, Jung Seung Lee1,2,3,11, Hyunjoon Kim1,2,3, Adam J Wentworth1,2,3, Sidharth Shankar8, Ghee Rye Lee8, Jianling Bi5, Emily Witt5, Keiko Ishida1,2,3, Alison Hayward3,12, Johannes L P Kuosmanen2,3, Josh Jenkins2,3, Jacob Wainer1,2,3, Aya Aragon2, Kaitlyn Wong1, Christoph Steiger1,2,3, William R Jeck13, Dustin E Bosch14, Mitchell C Coleman7, Douglas R Spitz7, Michael Tift9, Robert Langer2,3, Leo E Otterbein8, Giovanni Traverso1,2,3.   

Abstract

Carbon monoxide (CO) has long been considered a toxic gas but is now a recognized bioactive gasotransmitter with potent immunomodulatory effects. Although inhaled CO is currently under investigation for use in patients with lung disease, this mode of administration can present clinical challenges. The capacity to deliver CO directly and safely to the gastrointestinal (GI) tract could transform the management of diseases affecting the GI mucosa such as inflammatory bowel disease or radiation injury. To address this unmet need, inspired by molecular gastronomy techniques, we have developed a family of gas-entrapping materials (GEMs) for delivery of CO to the GI tract. We show highly tunable and potent delivery of CO, achieving clinically relevant CO concentrations in vivo in rodent and swine models. To support the potential range of applications of foam GEMs, we evaluated the system in three distinct disease models. We show that a GEM containing CO dose-dependently reduced acetaminophen-induced hepatocellular injury, dampened colitis-associated inflammation and oxidative tissue injury, and mitigated radiation-induced gut epithelial damage in rodents. Collectively, foam GEMs have potential paradigm-shifting implications for the safe therapeutic use of CO across a range of indications.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35767653      PMCID: PMC9576196          DOI: 10.1126/scitranslmed.abl4135

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   19.319


  44 in total

1.  A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS.

Authors:  Laura E Fredenburgh; Mark A Perrella; Diana Barragan-Bradford; Dean R Hess; Elizabeth Peters; Karen E Welty-Wolf; Bryan D Kraft; R Scott Harris; Rie Maurer; Kiichi Nakahira; Clara Oromendia; John D Davies; Angelica Higuera; Kristen T Schiffer; Joshua A Englert; Paul B Dieffenbach; David A Berlin; Susan Lagambina; Mark Bouthot; Andrew I Sullivan; Paul F Nuccio; Mamary T Kone; Mona J Malik; Maria Angelica Pabon Porras; Eli Finkelsztein; Tilo Winkler; Shelley Hurwitz; Charles N Serhan; Claude A Piantadosi; Rebecca M Baron; B Taylor Thompson; Augustine Mk Choi
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis.

Authors:  Henry P Parkman; William L Hasler; Robert S Fisher
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

3.  The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase.

Authors:  R Tenhunen; H S Marver; R Schmid
Journal:  Proc Natl Acad Sci U S A       Date:  1968-10       Impact factor: 11.205

4.  Expression of heme oxygenase-1 can determine cardiac xenograft survival.

Authors:  M P Soares; Y Lin; J Anrather; E Csizmadia; K Takigami; K Sato; S T Grey; R B Colvin; A M Choi; K D Poss; F H Bach
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

5.  Carbon monoxide promotes gastric wound healing in mice via the protein kinase C pathway.

Authors:  Tomohisa Takagi; Yuji Naito; Kazuhiko Uchiyama; Katsura Mizuhima; Takahiro Suzuki; Ryusuke Horie; Ikuhiro Hirata; Hisato Tsuboi; Toshikazu Yoshikawa
Journal:  Free Radic Res       Date:  2016-06-02

6.  Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial.

Authors:  Thomas Zilli; Ciro Franzese; Marta Bottero; Niccolò Giaj-Levra; Robert Förster; Daniel Zwahlen; Nikolaos Koutsouvelis; Aurelie Bertaut; Julie Blanc; Giuseppe Roberto D'agostino; Filippo Alongi; Matthias Guckenberger; Marta Scorsetti; Raymond Miralbell
Journal:  Radiother Oncol       Date:  2019-08-17       Impact factor: 6.280

Review 7.  Where is the Clinical Breakthrough of Heme Oxygenase-1 / Carbon Monoxide Therapeutics?

Authors:  Christopher P Hopper; Lorenz Meinel; Christoph Steiger; Leo E Otterbein
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

Review 8.  Gastrointestinal radiation injury: symptoms, risk factors and mechanisms.

Authors:  Abobakr K Shadad; Frank J Sullivan; Joseph D Martin; Laurence J Egan
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

9.  Organic carbon monoxide prodrug, BW-CO-111, in protection against chemically-induced gastric mucosal damage.

Authors:  Dominik Bakalarz; Marcin Surmiak; Xiaoxiao Yang; Dagmara Wójcik; Edyta Korbut; Zbigniew Śliwowski; Grzegorz Ginter; Grzegorz Buszewicz; Tomasz Brzozowski; Jakub Cieszkowski; Urszula Głowacka; Katarzyna Magierowska; Zhixiang Pan; Binghe Wang; Marcin Magierowski
Journal:  Acta Pharm Sin B       Date:  2020-08-24       Impact factor: 11.413

Review 10.  Mechanisms of acetaminophen-induced liver injury and its implications for therapeutic interventions.

Authors:  Mingzhu Yan; Yazhen Huo; Shutao Yin; Hongbo Hu
Journal:  Redox Biol       Date:  2018-04-22       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.